#TradFi交易分享挑战

How Hantavirus is Turning mRNA Back into a "Hold" Stock

As the cruise ship pandemic intensifies and global concern over hantavirus rises, Moderna, which had gradually faded from investors' view, is once again becoming a market focus. The amplification of the public health event combined with the company's new technological narrative is rewriting the investment logic of this biotech company.

　　Pandemic Accelerates Vaccine Demand
Since the outbreak on the "Hondius" cruise ship, confirmed and suspected cases worldwide have continued to increase. Although the World Health Organization currently assesses the global public health risk as "low," countries like South Korea, the United States, and parts of Europe have initiated virus monitoring plans. The spread of infectious diseases has reignited market attention on pandemic preparedness vaccine reserves, and the advantages of mRNA technology in rapidly responding to new viruses are once again highlighted.

Moderna's Hantavirus Candidate Vaccine

Moderna is currently the only large biotech company with an mRNA hantavirus vaccine in clinical stages. The candidate vaccine developed in partnership with a Korean university has completed multiple preclinical studies. If granted emergency use authorization or included in government strategic reserves, it could generate billions of dollars in revenue for the company. Although the vaccine is still years away from market launch and currently on hold due to funding issues, the spread of a new wave of infections may prompt regulators to accelerate approval or funding processes. Analysts note that the pandemic's hotness once again reminds the market that Moderna's mRNA platform should not be valued solely based on its COVID-19 business.

　　Valuation Reshaping and Financial Outlook

Moderna's current market cap is about $25 billion, down over 80% from its 2021 peak, approaching its cash holdings. The company expects COVID-19 and RSV vaccine revenues to be around $2-2.5 billion in 2026 and plans to break even by 2026.

The CEO stated that the company is refocusing resources on the "platform value" for pandemic prevention, and the hantavirus incident just confirms its strategic direction. Investors should not view it merely as a vaccine stock but as a technology platform capable of rapidly responding to global health threats. Several analysts have upgraded Moderna's rating to "Buy," with a median target price of $120, implying about 60% upside. On Friday morning, Moderna's stock rose about 5%. Year-to-date, the stock has increased approximately 18%. Investors should watch whether the pandemic continues to intensify and whether the hantavirus vaccine candidate can secure new funding or emergency authorization. The company plans to reveal more about its long-term virus prevention platform at its investor day in June. $MRNA $JPN225 $XAGUSD